Strategic Timing of Anti-Retroviral Treatment (START Study)

Project Timeline

2016 – Now

The START trial was designed to address the question: In HIV-1 (subsequently referred to as HIV) infected asymptomatic participants with a CD4+ count greater than 500 cells/mm3, is immediate use of antiretroviral therapy (ART) superior to deferral of ART until the CD4+ count declines to 350 cells/mm3 or AIDS develops in terms of morbidity and mortality? The study is being conducted at 237 sites in 35 countries. Global enrolment closed with 4,688 participants enrolled.

External Links

Kirby Institute – University of New South Wales

Strategic Timing of Antiretroviral Treatment (START) – ClinicalTrials.gov

Events

Other Current Projects

WHO: Strengthening Civil Society Engagement in the COVID-19 Response at the National and Local Levels - Vaccination, Decarceration and Community Reintegration of People in Prison amidst COVID-19 in Malaysia

An Open-label, Randomized, Adaptive Cross-over Interventional Study to Evaluate the Efficacy of Tocilizumab versus Corticosteroids in hospitalised COVID-19 patients with high risk of progression (STORM Study)

National Health and Medical Research: Towards a functional cure for Hepatitis B Virus: exploiting lessons from HBV-HIV co-infection (COMMIT Study)